Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Summary

Meet our Teams, Polyplus at booth #32 and Xpress Biologics at booth #33 during 11th AIS ( Antibody Industrial Symposium) 2023, in Tours, France, June 22-23, 2023. Don't miss the opportunity to hear our talk and poster presentation on Plasmid engineering technology from Polyplus: How to fast track your rmAbs Discovery.

Our team

Presenters:

    Sylvain Julien Ph.D., Innovation Director e-Zyvec at Polyplus®. 

Talk : Plasmid engineering technology from Polyplus: How to fast track your rmAbs Discovery
Time : Wednesday June 23, 2023 : 11:00 AM – 11:10 AM CET

Summary of presentation : Early stage of recombinant monoclonal antibodies requires to assess as many as possible candidates in the minimal time as possible. Two bottlenecks can be considered: 1- the ability of generating dozens or hundreds of molecular constructs (plasmids) based on rational design; 2- the yield of expression of antibodies in small scale culture, to obtain rapidly quantity enough to conduct characterization. Generating multiple plasmids in parallel is by essence the benefit brought by the e-Zyvec’s DNA assembly technology. Here we show case how we used this technology to design and compare several plasmid layouts and identify those that will ensure the best yields in small scale culture.


Poster : Improving mAbs yield and quality through plasmid engineering

By :  Vianey DELEPLACE, Narciso COSTA, Léa KENGNE KAMKUI, Marie HAUTIERE, Didier BOQUE , Amaury HERBET, Sylvain JULIEN

Recombinant monoclonal antibodies (rmAbs) will become part of the therapeutical arsenal for numerous pathologies, The generalization of their usage will be driven by faster development program and lower production costs, both criteria being directly dependent on the productivity of our bioprocesses. During the past decades impressive progresses have been made regarding the bioproduction equipment’s, cell models and purification processes. The improvement of the biomolecular components, that are the plasmids, has somewhat lagged behind such developments. With the booming of molecular technologies of DNA assembly methods, including the proprietary e-Zyvec® method from Polyplus®, we have new opportunities to explore the potential of plasmid engineering as another leverage to increase yield and quality of rmAbs bioproduction.

Download Poster